Cocrystal Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COCP research report →
Price Chart
About the company
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses.
- CEO
- James E. Sapirstein
- IPO
- 2012
- Employees
- 10
- HQ
- Bothell, WA, US
Get TickerSpark's AI analysis on COCP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.30M
- P/E
- -1.20
- PEG
- -0.09
- P/S
- 42.95
- P/B
- 6.32
- EV/EBITDA
- -1.33
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -2645.98%
- Net Margin
- -2605.29%
- ROE
- -320.01%
- ROIC
- -292.73%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-5,055,000+59.7%
- Op Income
- $-9,019,000
- Net Income
- $-8,831,000+49.5%
- EPS
- $-0.78+54.7%
- OCF Growth
- +50.3%
- FCF Growth
- +50.3%
- 52W High
- $2.03
- 52W Low
- $0.76
- 50D MA
- $1.06
- 200D MA
- $1.10
- Beta
- 1.61
- RSI (14)
- 41
- Avg Volume
- 41.30K
No earnings-call transcripts are available for COCP yet.
- Free Float
- 66.5%
- Shares Outstanding
- 19.26M
- Float Shares
- 12.81M
of shares held by institutions
26 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 358.23K | 0 |
| Vanguard Group Inc | 263.99K | ▼ 4.09K |
| Two Sigma Investments, LP | 175.38K | ▲ 175.38K |
| Renaissance Technologies LLC | 175.00K | ▼ 4.63K |
| Geode Capital Management, LLC | 124.45K | ▲ 48.24K |
| Vanguard Fiduciary Trust Co | 81.56K | ▲ 57.54K |
| Blackrock, Inc. | 73.75K | 0 |
| Citadel Advisors LLC | 45.12K | ▲ 45.12K |
| Neuberger Berman Group LLC | 31.89K | 0 |
| Xtx Topco Ltd | 29.34K | ▼ 6.69K |
| State Street Corp | 20.54K | 0 |
| Parallel Advisors, LLC | 12.57K | 0 |
Held by 20 ETFs
Biggest fund positions in COCP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 12, 26 | Brosgart Carol L | other | 0 |
| Aug 5, 26 | FROST PHILLIP MD ET AL | buy | 10,000 |
| Aug 3, 26 | FROST PHILLIP MD ET AL | buy | 75,000 |
| Jun 3, 26 | SAPIRSTEIN JAMES | other | 0 |
| Feb 24, 26 | FROST PHILLIP MD ET AL | buy | 20,000 |
| Feb 6, 26 | FROST PHILLIP MD ET AL | buy | 50,000 |
| Jan 9, 26 | Kornberg Roger D. | other | 24,615 |
| Jan 9, 26 | PFENNIGER RICHARD C JR | other | 16,410 |
| Jan 9, 26 | Lee Sam | other | 49,229 |
| Jan 9, 26 | Hassan Fred | other | 16,410 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our COCP coverage
Recent articles, reports, and earnings notes.
No research on COCP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate COCP report →Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 15
Cocrystal Pharma (NASDAQ:COCP) Shares Cross Above 200-Day Moving Average – What’s Next?
defenseworld.net · Nov 10
Xeris Biopharma (NASDAQ:XERS) vs. Cocrystal Pharma (NASDAQ:COCP) Head-To-Head Contrast
defenseworld.net · Nov 3
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
globenewswire.com · Sep 9
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors
globenewswire.com · Aug 17
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
globenewswire.com · Aug 3
Financial Contrast: Cocrystal Pharma (NASDAQ:COCP) vs. Zevra Therapeutics (NASDAQ:ZVRA)
defenseworld.net · Aug 3
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
globenewswire.com · Jun 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.